{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:44Z","timestamp":1760028224590},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T00:00:00Z","timestamp":1405987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be active in newly diagnosed and relapsed patients with follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. Many studies suggest that the prognosis of patients with FL may improve when it is used in combination with chemotherapy. Despite these advances, the disease remains essentially incurable with standard therapy, and novel approaches to treatment are needed because optimal therapy is not defined. The combination of chlorambucil\u2013rituximab is one of several standard treatment options for FL. Here, we considered data arising from 75 patients with newly diagnosed FL at the European Institute of Oncology treated with the combination of rituximab plus chlorambucil. The aim of this study was to evaluate the efficacy and safety of chlorambucil and rituximab, delivered 6\u2009mg\/m<jats:sup>2<\/jats:sup>\/day orally for 6\u2009weeks and 375\u2009mg\/m<jats:sup>2<\/jats:sup> in a standard 4\u2010weekly schedule, respectively. Patients responding to the induction therapy received a prolonged therapy with four additional cycles of chlorambucil plus rituximab. Seventy\u2010one patients (94.6%) completed the treatment; four patients discontinued treatment because of grade 3\u20134 hematological toxicity. The overall response rate was 97.3% including 74.7% of complete responses. Only two patients had a stable disease at revaluation after treatment. With a median follow\u2010up of 57\u2009months, 72 patients (96%) are alive. Median event\u2010free survival (EFS) and median overall survival (OS) were not reached; 5\u2010year OS rate was 98.4%. The 5\u2010year EFS was 71.3%. By univariate and multivariate analyses, elevated beta\u20102 microglobulin levels and partial responses to therapy were correlated with worse EFS. These results suggest that the combination of chlorambucil and rituximab is an active and safe regimen in patients with newly diagnosed FL, principally in those with low tumour burden and favourable prognostic factors. Copyright \u00a9 2014 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.2154","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T05:53:17Z","timestamp":1406008397000},"page":"129-135","source":"Crossref","is-referenced-by-count":12,"title":["Chlorambucil\u2013rituximab as first\u2010line therapy in patients affected by follicular non\u2010Hodgkin's lymphoma: a retrospective single\u2010centre study"],"prefix":"10.1002","volume":"33","author":[{"given":"Giovanni","family":"Martinelli","sequence":"first","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Montoro","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Vanazzi","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Andreola","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Liptrott","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Radice","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Negri","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Preda","sequence":"additional","affiliation":[{"name":"Division of Radiology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[{"name":"Division of Pathology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Laszlo","sequence":"additional","affiliation":[{"name":"Division of Clinical Hemato\u2010oncology European Institute of Oncology  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"220","volume-title":"World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Harris NL","year":"2008"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/annonc\/mdp148","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow\u2010up","volume":"4","author":"Dreyling M","year":"2009","journal-title":"Ann Oncol"},{"key":"e_1_2_8_4_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_8_5_1","first-page":"380","article-title":"Follicular lymphoma","volume":"34","author":"De Angelis F","year":"2012","journal-title":"Exp Oncol"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi320"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low\u2010tumor burden follicular lymphoma (FL): survival analyses with extended follow\u2010up (F\/Up) of 7 years","volume":"108","author":"Colombat P","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1802.1802","article-title":"Rituximab maintenance treatment for a maximum of 5\u2009years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03","volume":"116","author":"Taverna CJ","year":"2010","journal-title":"Blood"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04586.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601078134"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6112.533"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.503"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1674"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06378.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902741497"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.405.405","article-title":"Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first\u2010line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StIL (Study Group Indolent Lymphomas, Germany)","volume":"114","author":"Rummel MJ","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"10","author":"Gallagher CJ","year":"1986","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/2.suppl_2.141"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6272"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23668"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_8_31_1","article-title":"Prognostic role of histological grade 3a in follicular lymphoma in the rituximab era. Results of an F2\u2010study database","volume":"31","author":"Bellei M","year":"2013","journal-title":"Hematol Oncol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11502"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2154","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:34:38Z","timestamp":1696394078000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1002\/hon.2154"],"URL":"https:\/\/doi.org\/10.1002\/hon.2154","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}